Lenograstim belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. Lenograstim induces a marked increase in peripheral blood neutrophil counts within 24 hours of administration.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L03AA10 | Lenograstim | L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| GRANOCYTE Powder and solvent for solution for injection/infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Lenograstim is an active ingredient of these brands:
Cyprus (CY)Finland (FI)France (FR)Ireland (IE)Japan (JP)Lithuania (LT)Malta (MT)Singapore (SG)South Africa (ZA)Spain (ES)Tunisia (TN)Turkey (TR)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
